These findings position S100A2 as a potential therapeutic target for overcoming drug resistance and improving treatment efficacy in OSCC. Further mechanistic studies and in vivo validation are warranted to explore its translational relevance in clinical oncology.
Kumar et al. (Wed,) studied this question.